A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

CLINICALTRIALS.GOV IDENTIFIER	RECRUITMENT STATUS	FIRST POSTED	LAST UPDATE POSTED
NCT03906526	RECRUITING	APRIL 8, 2019	FEBRUARY 1, 2021

STUDY DESCRIPTION

Brief Summary

This is an open label, Phase 1b pre-operative window of opportunity biomarker trial to analyze the combination of intravenous (IV) anti-PD-1 inhibitor, nivolumab, given along with toll-like receptor 8 (TLR 8) agonist motolimod delivered either subcutaneously (SC) or by intratumoral injection (IT) in subjects with squamous cell carcinoma of the head and neck (SCCHN). Subjects with previously untreated, resectable SCCHN, will be recruited onto this trial and will initially undergo pre-treatment diagnostic imaging and biological sample collection. These subjects will undergo pre-operative study treatment for a 3 to 4-week period prior to a scheduled surgical resection.

Condition or Disease: Carcinoma, Squamous Cell

Intervention/treatment: Drug: VTX-2337
Drug: Nivolumab

Phase: Phase 1

DETAILED DESCRIPTION

N/A

STUDY DESIGN

Study Type: Interventional

Estimated Enrollment : 72 participants

Intervention Model : Parallel Assignment

Masking: None (Open Label) ()

Primary Purpose: Treatment

Official Title: A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Actual Study Start Date: July 2019

Estimated Primary Completion Date: May 2022

Estimated Study Completion Date: August 2022

ARMS AND INTERVENTIONS

Arm	Intervention/treatment
Experimental: Combination Arm 3: Nivolumab and Motolimod Nivolumab IV every 2 weeks and Motolimod IT injection weekly	Drug: VTX-2337 Motolimod Drug: Nivolumab IV Nivolumab
Experimental: Combination Arm 4: Nivolumab and Motolimod Nivolumab IV every 2 weeks and Motolimod SC injection weekly	Drug: VTX-2337 Motolimod Drug: Nivolumab IV Nivolumab
Experimental: Monotherapy Arm 2: Motolimod Motolimod IT injection weekly	Drug: VTX-2337 Motolimod
Experimental: Monotherapy Arm 1: Nivolumab Nivolumab IV every 2 weeks	Drug: Nivolumab IV Nivolumab

OUTCOME MEASURES

Primary Outcome Measures: 1. Numbers of CD8+ T cells within the tumor pre-treatment and post-surgery [Time Frame: Screening through Study Day 52]
Tumor immune modulation will be evaluated by counting the number of tumor infiltration CD8+ T cells before and after treatment.

Secondary Outcome Measures: 1. Number of Patients With adverse events that lead to delay in resection [Time Frame: Screening through Study Day 52]
Study will evaluate the number of patients who experience adverse events that lead to a significant delay in surgical resection.

2. Evaluation of safety and tolerability of nivolumab, motolimod and the combination of nivolumab with motolimod [Time Frame: Up to approximately 112 days]
Subject will be monitored for AEs both during treatment and for a specified period after last dose of study treatment. AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

ELIGIBILITY CRITERIA

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:
- Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
- Subject has Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
- Subject has a new clinical or pathologic diagnosis of resectable HPV+ or HPV- SCCHN of the oral cavity, pharynx, or larynx
- Macroscopic complete resection of the primary tumor must be planned and subjects should have no medical contraindication to surgery.
- Subject consents to and has tumor accessible for tumor biopsy pre-treatment.
- Subjects must have acceptable hematopoietic, liver, renal, and coagulation function as assessed by laboratory tests.

Exclusion Criteria:
- Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
- Subject has unresectable or inoperable tumors
- Subject has primary tumors of the sinuses, paranasal sinuses, or nasopharynx, or unknown primary tumors
- Subject has evidence of distant metastasis
- Subject is a pregnant or nursing female.
- Subject has active or uncontrolled infection including known HIV infection or known chronic hepatitis B or C.
- Subject has active autoimmune disease.
- Subject has clinically significant ophthalmologic disease.

CONTACTS AND LOCATIONS

Contacts

Contact:

Locations

United States, Alabama	University of Alabama at Birmingham	Birmingham
United States, California	University of California Los Angeles	Los Angeles
United States, Iowa	University of Iowa Hospitals and Clinics	Iowa City
United States, Kansas	University of Kansas	Westwood
United States, Massachusetts	Boston University	Boston
United States, Missouri	Washington University	Saint Louis
United States, North Carolina	University of North Carolina	Chapel Hill
United States, Ohio	University of Cincinnati	Cincinnati
United States, Ohio	The Ohio State University Comprehensive Cancer Center	Columbus
United States, Pennsylvania	University of Pittsburgh Medical Center Hillman Cancer Center	Pittsburgh
United States, South Dakota	Sanford Cancer Center	Sioux Falls

Sponsors and Collaborators

Celgene

Investigator

Study Director :	Amar Patel, MD	Celgene Corporation

MORE INFORMATION

Responsible Party : Celgene

ClinicalTrials.gov Identifier : NCT03906526

Other Study ID Numbers : VTX-2337-HN-001, U1111-1223-3488

First Posted : April 8, 2019

Last Update Posted :	February 1, 2021
Last Verified :	January 2021
Individual Participant Data (IPD) Sharing Statement:	
Plan to Share IPD:	Yes
Plan Description:	Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
Supporting Materials:	Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code
Time Frame:	See Plan Description
Access Criteria:	See Plan Description
URL:	https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No
Keywords provided by Celgene:	*Motolimod* *Nivolumab* *Head and Neck Cancer* *Squamous Cell Carcinoma Checkpoint inhibitor* *anti-PD1 inhibitor* *TLR 8 agonist*
Additional relevant MeSH terms :	*Carcinoma* *Carcinoma, Squamous Cell*